{"id":21051,"date":"2026-01-19T16:13:02","date_gmt":"2026-01-19T07:13:02","guid":{"rendered":"https:\/\/www.waseda.jp\/inst\/wias\/?p=21051"},"modified":"2026-02-12T09:26:25","modified_gmt":"2026-02-12T00:26:25","slug":"%e9%ab%98%e7%ad%89%e7%a0%94%e7%a9%b6%e6%89%80%e3%82%bb%e3%83%9f%e3%83%8a%e3%83%bc%e3%82%b7%e3%83%aa%e3%83%bc%e3%82%ba-%e3%80%90%e6%96%b0%e3%81%97%e3%81%84%e4%b8%96%e7%95%8c%e5%8f%b2%e5%83%8f-8-5-1-3-8","status":"publish","type":"post","link":"https:\/\/www.waseda.jp\/inst\/wias\/news\/2026\/01\/19\/21051\/","title":{"rendered":"WIAS Top Runners’ Lecture Collection
AI\u3068\u30d5\u30a1\u30a4\u30ca\u30f3\u30b9\u30ef\u30fc\u30af\u30b7\u30e7\u30c3\u30d7 “Investing in AI: Clinical Trial Efficiency and Market Reaction”\uff082\/18\uff09"},"content":{"rendered":"

WIAS Top Runners’ Lecture Collection
\nAI\u3068\u30d5\u30a1\u30a4\u30ca\u30f3\u30b9\u30ef\u30fc\u30af\u30b7\u30e7\u30c3\u30d7 “Investing in AI: Clinical Trial Efficiency and Market Reaction”\uff082\/18\uff09<\/h2>\n

\u4e3b \u65e8 \/ Abstract<\/h5>\n

AI\u304c\u4f01\u696d\u3084\u793e\u4f1a\u3001\u7279\u306b\u96c7\u7528\u3084\u96c7\u7528\u6761\u4ef6\u306b\u3069\u306e\u3088\u3046\u306a\u5f71\u97ff\u3092\u4e0e\u3048\u308b\u306e\u304b\u306f\u793e\u4f1a\u7684\u306b\u3082\u5b66\u8853\u7684\u306b\u3082\u6975\u3081\u3066\u91cd\u8981\u306a\u554f\u984c\u3067\u3042\u308b\u3002\u3053\u306e\u5206\u91ce\u306b\u3064\u3044\u3066\u3001\u3053\u306e\u5206\u91ce\u306e\u30c8\u30c3\u30d7\u30e9\u30f3\u30ca\u30fc\u306eSean Cao\u6559\u6388\u306b\u3054\u8b1b\u6f14\u3092\u3044\u305f\u3060\u304d\u307e\u3059\u3002<\/p>\n

\u30d7\u30ed\u30b0\u30e9\u30e0 \/ Program<\/h5>\n

Sean Cao\u6559\u6388\u306bAI\u3068\u30d5\u30a1\u30a4\u30ca\u30f3\u30b9\u306b\u3064\u3044\u3066\u3001\u3054\u81ea\u8eab\u306e\u904e\u53bb\u306e\u7814\u7a76\u306b\u3064\u3044\u3066\u8b1b\u6f14\u3092\u3057\u3066\u3044\u305f\u3060\u304d\u307e\u3059\u3002\u6559\u6388\u306e\u7814\u7a76\u306f\u3001AI\u3068\u30d5\u30a1\u30a4\u30ca\u30f3\u30b9\uff0f\u4f1a\u8a08\u306e\u878d\u5408\u306b\u304a\u3051\u308b\u6700\u5148\u7aef\u3068\u3057\u3066\u56fd\u969b\u7684\u306b\u9ad8\u304f\u8a55\u4fa1\u3055\u308c\u3066\u304a\u308a\u3001\u4e16\u754c\u306e\u4e3b\u8981\u30e1\u30c7\u30a3\u30a2\u3067\u3082\u3057\u3070\u3057\u3070\u53d6\u308a\u4e0a\u3052\u3089\u308c\u3066\u3044\u307e\u3059\u3002AI\u304c\u91d1\u878d\u696d\u754c\u306e\u696d\u52d9\u30fb\u96c7\u7528\u7b49\u306b\u4e0e\u3048\u305f\u5b9f\u8a3c\u7814\u7a76\u3092\u4e2d\u5fc3\u306b\u3001\u6700\u8fd1\u306eAI\u3068\u30d5\u30a1\u30a4\u30ca\u30f3\u30b9\u306e\u7814\u7a76\u306b\u3064\u3044\u3066\u3054\u8b1b\u6f14\u3092\u3044\u305f\u3060\u304d\u307e\u3059\u3002<\/p>\n

13:10\uff5e15:10\u3000”Investing in AI: Clinical Trial Efficiency and Market Reaction” by Professor Sean Cao<\/p>\n

While artificial intelligence (AI) is heralded as a panacea, we still grapple with the optimal ways to harness its potential. Using project-level clinical trial data, we find that pharmaceutical firms’ AI investment, on average, does not improve trial efficiency or financial prospects. We identify the contexts where AI adds value and when it does not. Overall, complementary human expertise, balanced regulation, and optimization objective clarity are critical for realizing AI’s potential. When these factors come together, AI can improve efficiency and financial prospects of clinical trials, which in turn enhances social welfare. Our analysis addresses an emerging question: not whether firms should adopt AI, but how they can do so effectively.
\n(Please click here to see further information of this paper.)<\/a><\/p>\n

\u767b\u58c7\u8005 \/ Speaker<\/h5>\n

\u30b7\u30e7\u30fc\u30f3\u30fb\u30ab\u30aa(Sean Cao)
\n\u30e1\u30ea\u30fc\u30e9\u30f3\u30c9\u5927\u5b66\u8cc7\u672c\u5e02\u5834\u306e\u305f\u3081\u306eAI\u30a4\u30cb\u30b7\u30a2\u30c1\u30d6\u7814\u7a76\u30bb\u30f3\u30bf\u30fc\u6240\u9577\u30fb\u5171\u540c\u5275\u7acb\u8005\u3002\u30d5\u30a1\u30a4\u30ca\u30f3\u30b9\u306b\u304a\u3051\u308bAI\u306e\u5fdc\u7528\u306b\u95a2\u3059\u308b\u4e16\u754c\u7684\u306a\u7814\u7a76\u8005\u3002”Man vs. Machine to Man + Machine: The Art and AI of Stock Analyses”\u3084”How to Talk When Machines are Listening: Corporate Disclosure in the Age of AI”\u306f\u3001Journal of Financial Economics \u3084Review of Financial Studies\u3068\u3044\u3063\u305f\u30c8\u30c3\u30d7\u30b8\u30e3\u30fc\u30ca\u30eb\u306b\u63b2\u8f09\u3055\u308c\u305f\u3060\u3051\u3067\u306f\u306a\u304f\u3001\u63b2\u8f09\u8ad6\u6587\u306b\u5bfe\u3059\u308b\u8cde(Fama-DFA\u8cde\uff08JFE\uff09,Michael J. Brennan\u8cde\uff08RFS\uff09\u3092\u53d7\u8cde\u3002
\nBiography<\/a>\u3000CV<\/a><\/p>\n

\u65e5\u3000\u6642 \/ Date&Time<\/h5>\n

2026\u5e742\u670818\u65e5\uff08\u6c34\uff0913:10\uff5e15:10 \/ February 18, 2026 (Wed.) 13:10 \u2013 15:10<\/p>\n

\u4f1a\u5834 \/ Venue<\/h5>\n

\u65e9\u7a32\u7530\u30ad\u30e3\u30f3\u30d1\u30b919\u53f7\u99287\u968e710\u6559\u5ba4 \/ Room 710, 7th Floor, Building 19, Waseda Campus, Waseda University<\/p>\n

\u5bfe\u3000\u8c61 \/ Prospected Audience<\/h5>\n

\u5b66\u90e8\u751f\u3001\u5927\u5b66\u9662\u751f\u3001\u6559\u54e1\u3001\u7814\u7a76\u8005
\nStudents, Graduate students, Faculty members, Research members<\/p>\n

\u8a00\u3000\u8a9e \/ Language<\/h5>\n

\u82f1\u8a9e \/ English<\/p>\n

\u4e3b\u3000\u50ac \/ Organizer<\/h5>\n

\u65e9\u7a32\u7530\u5927\u5b66 \u9ad8\u7b49\u7814\u7a76\u6240 \/ Waseda Institute for Advanced Study (WIAS)<\/p>\n

\u5171\u3000\u50ac \/ Co-Organizer<\/h5>\n

\u65e9\u7a32\u7530\u5927\u5b66\u5546\u5b66\u5b66\u8853\u9662\u7523\u696d\u7d4c\u55b6\u7814\u7a76\u6240 \/ Research Institute of Business Administration, Faculty of Commerce, Waseda University<\/p>\n

\u7533\u3000\u8fbc \/ Registration<\/h5>\n

\u4e8b\u524d\u7533\u8fbc\u307f\u4e0d\u8981 \/ Pre-registration not required<\/p>\n","protected":false},"excerpt":{"rendered":"

WIAS Top Runners’ Lecture Collection AI\u3068\u30d5\u30a1\u30a4\u30ca\u30f3\u30b9\u30ef\u30fc\u30af\u30b7\u30e7\u30c3\u30d7 “Investing in AI: Clinical Trial Efficiency […]<\/p>\n","protected":false},"author":6,"featured_media":2762,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[1],"tags":[24,26,28],"class_list":["post-21051","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","tag-events","tag-general","tag-research"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.waseda.jp\/inst\/wias\/wp-json\/wp\/v2\/posts\/21051","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.waseda.jp\/inst\/wias\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.waseda.jp\/inst\/wias\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.waseda.jp\/inst\/wias\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/www.waseda.jp\/inst\/wias\/wp-json\/wp\/v2\/comments?post=21051"}],"version-history":[{"count":2,"href":"https:\/\/www.waseda.jp\/inst\/wias\/wp-json\/wp\/v2\/posts\/21051\/revisions"}],"predecessor-version":[{"id":21269,"href":"https:\/\/www.waseda.jp\/inst\/wias\/wp-json\/wp\/v2\/posts\/21051\/revisions\/21269"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.waseda.jp\/inst\/wias\/wp-json\/wp\/v2\/media\/2762"}],"wp:attachment":[{"href":"https:\/\/www.waseda.jp\/inst\/wias\/wp-json\/wp\/v2\/media?parent=21051"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.waseda.jp\/inst\/wias\/wp-json\/wp\/v2\/categories?post=21051"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.waseda.jp\/inst\/wias\/wp-json\/wp\/v2\/tags?post=21051"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}